RxDoctor Payments DataLook up a doctor →

Daniel Carrasco, MD

Dermatology · Austin, TXNPI 1558345793

Payments from drug & device makers

$1,421,772in general payments, 2019–2025

Across 2,847 payments — averaging $499.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$198K
  • Pfizer$125K
  • Johnson & Johnson$124K
  • Galderma Laboratories, L.p.$122K
  • Lilly USA, LLC$121K
  • Amgen$116K
  • plus $616K from 41 others
$3,197in research payments, 2019–2025

Across 2 payments — averaging $1598.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • LEO Pharma AS$3K

What the payments were for

  • Consulting fees$80,1247%
  • Speaking & faculty fees$885,80781%
  • Travel & lodging$74,1567%
  • Food & beverage$47,1214%
  • Education$1,3090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,421,772 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$996,583
Medicare patients
904
Services billed
10,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab24$161,906
TremfyaGuselkumab11$154,462
JubliaEfinaconazole22$21,188
Doxycycline Hyclate255$11,554
OraceaDoxycycline Monohydrate11$11,357
Tavaborole15$2,194
ValacyclovirValacyclovir Hcl54$1,738
Clobetasol Propionate36$1,695
Triamcinolone Acetonide161$1,479
Clindamycin Phosphate33$1,223
Fluocinonide32$1,184
Ketoconazole62$1,129
Metronidazole12$934
Terbinafine Hcl46$831
Minoxidil47$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$124,007$154,46211 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$23,247$21,18822 claims
Galderma Laboratories, L.p.Oracea$121,619$11,35711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →